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The vgf gene shows delayed-early induction by neuronal Growth Factors. It 
encodes the VGF protein precursor (615/617 aa, in man/rat), which yields an incom-
pletely characterized neuropeptides, some of which are involved in synaptic strength-
ening, anti-depressant and anti-apoptotic actions. Proteomic studies revealed clear-cut 
reduction of a 4.8kD VGF fragment in human CS ﬂ uid from ALS patients. In primary 
cultures of spinal motoneurons from SOD1-G93A mice (as a model of ALS), exoge-
nous adenoviral expression of VGF attenuated excitotoxic injury. In the same animals, 
a decrease of VGF was seen in CSF and serum, in parallel to progression of muscle 
weakness. Hence, we aimed at delineating VGF multi-peptide profi les in (normal) rat 
motoneurons, as well as possible changes of such peptides in plasma from human 
ALS patients vs controls. Specifi c antisera were raised against short sequences at the 
C- and N-termini (“C-t”, and “N-t”) of the VGF precursor, and of known / predicted 
cleaved VGF peptides, and were used in immunohistochemistry and ELISA. Spinal 
cord, frontal cortex and brainstem samples were taken for immunohistochemistry 
from rats (N=9) perfused with 4% paraformaldehyde. Plasma was obtained from ALS 
and control subjects (N=26/14 respectively, age range: 50-60yrs). Immunohistochem-
istry showed selective localization of VGF peptides in motoneurons in all regions 
tested. In the frontal cortex, VGF C-t peptides were widely distributed in perikarya 
of internal layers (III-VI), and in axons in superfi cial layers (I-II). Axons and termi-
nal were brightly stained in the ventral horn of the spinal cord, and in a number of 
brainstem motor nuclei (trigeminal, facial, hypoglossal and ambigus N.). Conversely, 
VGF N-t antibodies labelled mostly perikarya in all areas tested, while NERP-1 and 
–2, and PGH (VGF422-430) peptides were restricted to occasional cell bodies in frontal 
cortex. In a few sections, PGH and TLQP-21(VGF556-576) labelling was seen in ven-
tral horn perikarya. As to human plasma, NERP-1 and –2 as well as PGH peptides 
showed a signifi cant reduction in ALS patients, versus controls (peptide concentra-
tion measured: 37%, 43% and 29% of controls, respectively, p<0.025), while C-t pep-
tides were unchanged. In conclusion, at least in rat several specifi c VGF peptides are 
selectively distributed in areas critical to ALS, while certain VGF peptides appear to 
decrease in plasma in advanced cases of ALS. A possible role for specifi c VGF pep-
tides in such disease is suggested. 
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